MapLight Therapeutics (MPLT) Depreciation & Amortization (CF) (2024 - 2025)
MapLight Therapeutics (MPLT) reported Depreciation & Amortization (CF) of $200000.0 for Q4 2025, little changed on a YoY basis from $201000.0 in Q4 2024, and up 100.0% sequentially from $100000.0 in Q3 2025.
MapLight Therapeutics (MPLT) Depreciation & Amortization (CF) (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Depreciation & Amortization (CF) data on file, last reported at $200000.0 in Q4 2025.
- For the quarter ending Q4 2025, Depreciation & Amortization (CF) changed 0.5% year-over-year to $200000.0; the trailing twelve-month figure through Dec 2025 stood at $701000.0 (changed N/A YoY), and the FY2025 full-year result was $600000.0, down 14.41% from the prior year.
- Depreciation & Amortization (CF) rose to $200000.0 in Q4 2025, from $100000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $201000.0 in Q4 2024 to a low of $100000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | MapLight Therapeutics | 305.82 Mn | 305.82 Mn | - | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |